882670-77-1

Basic information

• Product Name: 6-BROMO-N-METHYLQUINOXALIN-2-AMINE
• Synonyms: 6-BROMO-N-METHYLQUINOXALIN-2-AMINE;6-bromo-N-methylquinazolin-2-amine;6-Bromo-2-(N-methylamino)quinazoline;6-BROMO-N-METHYLQUINAZOLIN-2-AMINE(WX130288)
• CAS NO: 882670-77-1
• Molecular Formula: C₉H₈BrN₃
• Molecular Weight: 238.087
• Mol File: 882670-77-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 6-BROMO-N-METHYLQUINOXALIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-N-METHYLQUINOXALIN-2-AMINE(882670-77-1)
• EPA Substance Registry System: 6-BROMO-N-METHYLQUINOXALIN-2-AMINE(882670-77-1)

Safety Data

• Hazardous Substances Data: 882670-77-1(Hazardous Substances Data)

Usage

General Description

6-Bromo-N-methylquinoxalin-2-amine is a chemical compound with the molecular formula C10H8BrN3. It is a derivative of the quinoxaline ring system, containing a bromine atom and a methyl substituent. This chemical has potential applications in the pharmaceutical industry, particularly in the development of new drugs and pharmaceuticals. It may also be used in research and development activities related to the study of quinoxaline derivatives and their biological activities. Additionally, this compound may have other industrial uses and applications, although further research is likely needed to fully understand its full potential.

Upstream product

• 882672-05-1 6-bromo-2-chloroquinazoline 
• 74-89-5 methylamine 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 190273-89-3 6-bromoquinazolin-2-ylamine 

Downstream Products

• 882671-02-5 6-(5-amino-2-methylphenyl)-N-methylquinazolin-2-amine 
• 882671-29-6 6-(5-isothiocyanato-2-methylphenyl)-N-methylquinazolin-2-amine 
• 913067-91-1 N-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine 

Relevant articles and documents

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.